PART 01: EXECUTIVE SUMMARY PART 02: SCOPE OF THE REPORT • 2.1 Preface • 2.2 Preface • 2.3 Currency conversion rates for US$ PART 03: MARKET LANDSCAPE • Market ecosystem • Market characteristics • Market segmentation analysis PART 04: MARKET SIZING • Market definition • Market sizing 2018 • Market size and forecast 2018-2023 PART 05: FIVE FORCES ANALYSIS • Bargaining power of buyers • Bargaining power of suppliers • Threat of new entrants • Threat of substitutes • Threat of rivalry • Market condition PART 06: PIPELINE PART 07: MARKET SEGMENTATION BY TYPE • Market segmentation by type • Comparison by type • Intrahepatic cholangiocarcinoma - Market size and forecast 2018-2023 • Extrahepatic cholangiocarcinoma - Market size and forecast 2018-2023 • Market opportunity by type PART 08: CUSTOMER LANDSCAPE PART 09: GEOGRAPHIC LANDSCAPE • Geographic segmentation • Geographic comparison • North America - Market size and forecast 2018-2023 • Europe - Market size and forecast 2018-2023 • Asia - Market size and forecast 2018-2023 • ROW - Market size and forecast 2018-2023 • Key leading countries • Market opportunity PART 10: DRIVERS AND CHALLENGES • Market drivers • Market challenges PART 11: MARKET TRENDS PART 12: VENDOR LANDSCAPE • Overview • Landscape disruption • Competitive scenario PART 13: VENDOR ANALYSIS • Vendors covered • Vendor classification • Market positioning of vendors • Bristol-Myers Squibb Company • Eli Lilly and Company • F. Hoffmann-La Roche Ltd • Pfizer Inc. • Sanofi PART 14: APPENDIX • Research methodology • List of abbreviations   Exhibit 01: Global oncology therapeutics market Exhibit 02: Segments of global oncology therapeutics market Exhibit 03: Market characteristics Exhibit 04: Market segments Exhibit 05: Market definition - Inclusions and exclusions checklist Exhibit 06: Market size 2018 Exhibit 07: Global market Exhibit 08: Global market Exhibit 09: Five forces analysis 2018 Exhibit 10: Five forces analysis 2023 Exhibit 11: Bargaining power of buyers Exhibit 12: Bargaining power of suppliers Exhibit 13: Threat of new entrants Exhibit 14: Threat of substitutes Exhibit 15: Threat of rivalry Exhibit 16: Market condition - Five forces 2018 Exhibit 17: Global cholangiocarcinoma therapeutics market pipeline Exhibit 18: Global cholangiocarcinoma therapeutics market pipeline Exhibit 19: Type - Market share 2018-2023 (%) Exhibit 20: Comparison by type Exhibit 21: Intrahepatic cholangiocarcinoma - Market size and forecast 2018-2023 ($ millions) Exhibit 22: Intrahepatic cholangiocarcinoma - Year-over-year growth 2019-2023 (%) Exhibit 23: Extrahepatic cholangiocarcinoma - Market size and forecast 2018-2023 ($ millions) Exhibit 24: Extrahepatic cholangiocarcinoma - Year-over-year growth 2019-2023 (%) Exhibit 25: Market opportunity by type Exhibit 26: Customer landscape Exhibit 27: Market share by geography 2018-2023 (%) Exhibit 28: Geographic comparison Exhibit 29: North America - Market size and forecast 2018-2023 ($ millions) Exhibit 30: North America - Year-over-year growth 2019-2023 (%) Exhibit 31: Europe - Market size and forecast 2018-2023 ($ millions) Exhibit 32: Europe - Year-over-year growth 2019-2023 (%) Exhibit 33: Asia - Market size and forecast 2018-2023 ($ millions) Exhibit 34: Asia - Year-over-year growth 2019-2023 (%) Exhibit 35: ROW - Market size and forecast 2018-2023 ($ millions) Exhibit 36: ROW - Year-over-year growth 2019-2023 (%) Exhibit 37: Key leading countries Exhibit 38: Market opportunity Exhibit 39: Impact of drivers and challenges Exhibit 40: Vendor landscape Exhibit 41: Landscape disruption Exhibit 42: Vendors covered Exhibit 43: Vendor classification Exhibit 44: Market positioning of vendors Exhibit 45: Bristol-Myers Squibb Company - Vendor overview Exhibit 46: Bristol-Myers Squibb Company - Business segments Exhibit 47: Bristol-Myers Squibb Company - Organizational developments Exhibit 48: Bristol-Myers Squibb Company - Geographic focus Exhibit 49: Bristol-Myers Squibb Company - Key offerings Exhibit 50: Bristol-Myers Squibb Company - Key customers Exhibit 51: Eli Lilly and Company - Vendor overview Exhibit 52: Eli Lilly and Company - Business segments Exhibit 53: Eli Lilly and Company - Organizational developments Exhibit 54: Eli Lilly and Company - Geographic focus Exhibit 55: Eli Lilly and Company - Segment focus Exhibit 56: Eli Lilly and Company - Key offerings Exhibit 57: Eli Lilly and Company - Key customers Exhibit 58: F. Hoffmann-La Roche Ltd - Vendor overview Exhibit 59: F. Hoffmann-La Roche Ltd - Business segments Exhibit 60: F. Hoffmann-La Roche Ltd - Organizational developments Exhibit 61: F. Hoffmann-La Roche Ltd - Geographic focus Exhibit 62: F. Hoffmann-La Roche Ltd - Segment focus Exhibit 63: F. Hoffmann-La Roche Ltd - Key offerings Exhibit 64: F. Hoffmann-La Roche Ltd - Key customers Exhibit 65: Pfizer Inc. - Vendor overview Exhibit 66: Pfizer Inc. - Business segments Exhibit 67: Pfizer Inc. - Organizational developments Exhibit 68: Pfizer Inc. - Geographic focus Exhibit 69: Pfizer Inc. - Segment focus Exhibit 70: Pfizer Inc. - Key offerings Exhibit 71: Pfizer Inc. - Key customers Exhibit 72: Sanofi - Vendor overview Exhibit 73: Sanofi - Business segments Exhibit 74: Sanofi - Organizational developments Exhibit 75: Sanofi - Geographic focus Exhibit 76: Sanofi - Segment focus Exhibit 77: Sanofi - Key offerings Exhibit 78: Sanofi - Key customers Exhibit 79: Validation techniques employed for market sizing

Bristol-Myers Squibb Company Eli Lilly and Company F. Hoffmann-La Roche Ltd Pfizer Inc. and Sanofi